Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
The Journal of Headache and Pain|April 18, 2024
An economic evaluation of eptinezumab for the preventive treatment of migraine in the UK, with consideration for natural history and work productivityEdward Griffin, Gawain Shirley, Xin Ying Lee, et al.Neurology and Therapy|February 11, 2026
Sustained Efficacy of Eptinezumab in Participants with Migraine for Whom Prior Preventive Treatments Failed and Who Self-reported Psychiatric Comorbidities: Post Hoc Analysis of the Placebo-controlled DELIVER TrialPatricia Pozo-Rosich, Cristina Tassorelli, Line Pickering Boserup, et al.Journal of Patient-Reported Outcomes|December 18, 2024
Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trialPiero Barbanti, Susanne F Awad, Heather Rae-Espinoza, et al.Expert Review of Pharmacoeconomics & Outcomes Research|May 31, 2023
Estimating treatment effects on health utility scores for patients living with migraine: a post hoc analysis of the DELIVER trialLinus Jönsson, Stephane A Regnier, Steven Kymes, et al.The Journal of Headache and Pain|March 29, 2024
Structural equation modeling for identifying the drivers of health-related quality of life improvement experienced by patients with migraine receiving eptinezumabLinus Jönsson, Susanne F Awad, Stephane A Regnier, et al.Advances in Therapy|September 23, 2025
Number Needed to Treat and Cost Per Responder Analysis of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in Adults for Whom Prior Preventive Treatments have FailedDimos D Mitsikostas, Susanne F Awad, Rikke Kongerslev, et al.Patient Preference and Adherence|May 2, 2019
Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIIISusan Kearney, Leslie J Raffini, Tan P Pham, et al.European Journal of Neurology|March 16, 2026
Long-Term Improvements Following Initial Migraine Response in Eptinezumab-Treated Participants With Migraine for Whom 2-4 Prior Preventive Treatments Have FailedJessica Ailani, Messoud Ashina, Susanne F Awad, et al.European Journal of Neurology|December 15, 2025
Early and Sustained Shift in Headache Day Frequency Following Eptinezumab Treatment in Adults With Migraine for Whom 2-4 Previous Preventive Treatments Have Failed: A Post Hoc Analysis of the Randomized DELIVER TrialCristina Tassorelli, Amaal J Starling, Susanne F Awad, et al.Case Reports in Pulmonology|November 28, 2024
Brown-Colored Malignant Pleural Fluid With High Bilirubin Levels: A Case SeriesNai-Chien Huan, Larry Ellee Nyanti, Xin Ying Lee, et al.Pageof 3